The NuvaRing blood clot settlement resolved one of the most significant pharmaceutical liability cases involving hormonal contraception. Merck agreed to pay $100 million in February 2014 to settle claims that NuvaRing, a flexible contraceptive ring inserted into the vagina, increased the risk of blood clots and related cardiovascular events. The settlement was finalized in June 2014, resolving thousands of claims filed through a multi-district litigation (MDL) that had been consolidated since 2008. For example, a woman who suffered a pulmonary embolism while using NuvaRing could qualify for compensation, even though Merck did not admit that the product caused her condition.
This settlement represents a rare outcome in pharmaceutical litigation: a substantial payout without an admission of wrongdoing. Merck explicitly stated it settled “without denying or agreeing” to claims that NuvaRing was defective or negligently marketed. Approximately 3,800 people became eligible to receive compensation from the settlement fund, with payouts averaging around $58,000 per claimant. The litigation itself spanned more than a decade, beginning in 2008 and concluding in 2021, making it a lengthy process for affected users seeking resolution.
Table of Contents
- How Did the NuvaRing Settlement Arise and What Made It Significant?
- What Specific Health Conditions Were Covered in the Settlement?
- What Was the Timeline of the NuvaRing Litigation?
- How Much Money Was Available and How Much Did Claimants Receive?
- What Are the Common Issues Claimants Faced in the NuvaRing Settlement?
- What Does the Settlement Mean Regarding Merck’s Liability and Future Warnings?
- What Have We Learned About Hormonal Contraception and Blood Clot Risk?
How Did the NuvaRing Settlement Arise and What Made It Significant?
The NuvaRing litigation emerged from reports that users experienced serious blood clots—medically known as venous thromboembolism (VTE)—at higher rates than expected. Unlike traditional birth control pills that women take daily, NuvaRing releases hormones continuously while inserted for three weeks, then removed for a week-long break. This steady hormone release was thought to pose risks comparable to traditional oral contraceptives, but some research suggested the direct delivery of hormones through vaginal tissue created additional clotting risks. The lawsuits centered on whether Merck adequately warned doctors and consumers about these potential dangers before millions of women used the product.
The significance of this case lay partly in its size and scope. The consolidated multi-district litigation brought together claims from across the country, allowing for coordinated legal proceedings rather than scattered individual lawsuits. This structure helped plaintiffs share resources and coordinate legal strategies while also allowing the court to manage thousands of similar claims efficiently. By contrast, if each case had proceeded separately in different state courts, resolution could have taken decades longer and many claimants might have recovered nothing.
What Specific Health Conditions Were Covered in the Settlement?
The settlement covered injuries caused by serious blood clots and related conditions, specifically deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and in some cases, death. DVT occurs when a clot forms in a deep vein, usually in the legs, and can cause pain, swelling, and permanent damage if untreated. A pulmonary embolism happens when a clot travels to the lungs, potentially blocking blood flow and causing sudden difficulty breathing, chest pain, or sudden death. Stroke occurs when a clot blocks blood flow to the brain, causing permanent neurological damage or death.
The important limitation to understand: not every person who used NuvaRing and experienced these conditions automatically qualified for compensation. Claimants needed to prove that their condition was consistent with NuvaRing use and occurred while they were using the product or shortly after discontinuing it. A woman who suffered a stroke six months after stopping NuvaRing might have difficulty establishing causation, as other factors could have contributed. Additionally, the settlement did not cover minor conditions like occasional leg swelling or mild chest discomfort—only serious, objectively documented cardiovascular events qualified.
What Was the Timeline of the NuvaRing Litigation?
The NuvaRing multi-district litigation officially began in 2008, when the first cases were consolidated under MDL 1963 in the U.S. District Court for the Eastern District of Missouri. This initial formation allowed lawyers to begin the discovery process—exchanging documents, taking depositions, and building the scientific and medical evidence needed to support claims. For the next six years, the litigation proceeded through standard MDL procedures, with both plaintiffs and Merck exchanging millions of pages of documents and testimony.
Some cases settled individually, while others remained part of the broader class settlement negotiations. The settlement announcement came in February 2014, representing a breakthrough after years of litigation. However, the actual finalization process took several more months, with the settlement becoming final in June 2014. The MDL itself remained open for several more years, handling remaining administrative tasks and addressing claims disputes until it officially closed in September 2021. This extended timeline illustrates a common reality in pharmaceutical litigation: even after a settlement is announced, processing claims and resolving all outstanding issues can take years.
How Much Money Was Available and How Much Did Claimants Receive?
The $100 million settlement fund provided compensation to approximately 3,800 eligible claimants, resulting in an average payout of roughly $58,000 per person. However, it’s crucial to understand that this average masks significant variation. Claimants who suffered permanent disability—such as a stroke leaving them unable to work—typically received payments at the higher end of the range. Those with less severe outcomes, such as DVT requiring treatment but resolving without permanent complications, received lower payouts.
The specific amount each person received depended on factors including the severity of their injury, the cost of medical treatment, lost wages, and other damages. The $100 million figure, while substantial, represented a compromise between what plaintiffs might have recovered if they won at trial and what Merck was willing to pay. If the litigation had gone to trial in every case, some claimants might have recovered nothing if they lost, while others with strong evidence might have received multi-million-dollar verdicts. The settlement provided certainty: everyone with an approved claim received payment, even if that payment was less than a potential jury award. This tradeoff is typical in mass tort settlements, where certainty and speed come at the cost of potentially larger individual recoveries.
What Are the Common Issues Claimants Faced in the NuvaRing Settlement?
One significant challenge in the settlement process was proving causation—demonstrating that NuvaRing actually caused the claimant’s blood clot rather than some other factor. Women who were smokers, had a family history of blood clots, were overweight, or had other risk factors faced higher scrutiny during the claims process. A claims administrator had to review medical records, determine whether the clot event was consistent with NuvaRing use, and decide if the evidence supported compensation. This meant some claims were disputed or denied, requiring appeals or additional medical documentation.
Another limitation claimants should understand: the statute of limitations for filing claims in the settlement expired years ago. As of 2026, no new lawsuits against Merck for NuvaRing-related injuries are being accepted, and the litigation window has essentially closed. Anyone who used NuvaRing and suffered a blood clot but did not file a claim during the settlement period is now barred from recovering anything through this litigation. This is why it’s critical for users who experienced serious cardiovascular events while using NuvaRing to understand they may have missed an opportunity for compensation if they waited too long to pursue their claim.
What Does the Settlement Mean Regarding Merck’s Liability and Future Warnings?
Merck’s settlement without admitting liability—settling “without denying or agreeing” to the claims—is a detailed legal position that satisfied both parties but disappointed some claimants who wanted explicit acknowledgment that NuvaRing was defective. From Merck’s perspective, this settlement allowed the company to resolve the litigation while maintaining its legal position that the product is safe and properly labeled. The company continued to market and sell NuvaRing after the settlement, and the product remains available today.
The settlement did not result in the product being withdrawn from the market or significantly relabeled with new warnings. This outcome is typical in pharmaceutical settlements, where companies often negotiate settlements as business decisions rather than admissions of wrongdoing. Despite the settlement, some healthcare providers became more cautious about prescribing NuvaRing to women with additional risk factors for blood clots, and many women who used it during or after the litigation period were aware of the clotting risks in a way earlier users were not.
What Have We Learned About Hormonal Contraception and Blood Clot Risk?
The NuvaRing litigation contributed to broader understanding of cardiovascular risks associated with hormonal contraceptives. Medical research has consistently shown that all forms of hormonal birth control carry a small but real increased risk of blood clots compared to not using hormonal contraception. The specific risk with NuvaRing—whether it posed greater risk than oral contraceptives or other methods—remained debated in medical literature even after the settlement.
Some studies suggested the vaginal delivery system might increase risk slightly more than pills, while other research found minimal differences. What’s clear from the settlement and subsequent medical knowledge is that certain women should avoid NuvaRing altogether: those with a personal or family history of blood clots, women who smoke (especially over age 35), those with thrombophilic gene mutations, and women with other cardiovascular risk factors. The settlement focused attention on informed consent, making it essential that women understand the risks before using any hormonal contraceptive method.
You Might Also Like
- Westlake Services Payment Fee Class Action Settlement
- Uber $8.4 Million Driver Background Check Class Action Settlement
- Stryker Hip Implant Recall Class Action Settlement
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: